How much does Panitumumab cost?

Panitumumab is a monoclonal antibody used to treat metastatic colorectal cancer (mCRC). Panitumumab is an epidermal growth factor receptor (EGFR) antagonist that works by preventing the growth of cancer cells. It is given as an intravenous (IV) injection every 14 days, usually along with chemotherapy. Panitumumab is approved for first-line treatment with leucovorin, fluorouracil, and oxaliplatin (FOLFOX) and as monotherapy after disease progression on prior chemotherapy containing fluoropyrimidine, oxaliplatin, and irinotecan.

The U.S. Food and Drug Administration (FDA)-approved label states that panitumumab is indicated for use in wild-type RAS (mutated in neither KRAS or KRAS) mCRC. The label states that patients must use an FDA-approved test to confirm the absence of RAS mutations before starting panitumumab. Panitumumab is not indicated for the treatment of individuals with RAS-mutated colorectal cancer (in NRAS or KRAS) or when the RAS genetic variant status is unknown. Likewise anti-EGFR therapies should only be considered for treatment of individuals whose tumors are determined to be free of mutations after expanded RAS testing.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.